<DOC>
	<DOCNO>NCT02653872</DOCNO>
	<brief_summary>This phase 1 , non-randomized , fixed sequence , 3-period , drug-drug interaction study ass pharmacokinetics ( PK ) AZD7986 healthy subject administer alone combination multiple dose verapamil itraconazole diltiazem</brief_summary>
	<brief_title>A Phase I Study Assess PK AZD7986 Alone &amp; With Verapamil , Itraconazole Diltiazem Healthy Subjects</brief_title>
	<detailed_description>This study open-label , non-randomised , fixed sequence , 3-period study conduct single study centre ass PK AZD7986 healthy subject administer alone combination multiple dose verapamil itraconazole diltiazem . An adaptive design interim analysis PK data Periods 1 2 used determine itraconazole diltiazem administer combination AZD7986 Period 3 . Treatments administer fixed order separate washout period : period 1 - single AZD7986 ( 25 mg ) Day 1 ( 1 hour food ) , washout 7 day period 2 - verapamil ( 240 mg extend release formulation ) daily 1 hour food ( Day 1 10 ) single dose AZD7986 ( 25 mg ) 1 hour food ( Day 5 ) , washout period 14 day period 3 - subject interim pharmacokinetic analysis AZD7986 alone compare AZD7986 verapamil combine , either itraconazole ( 200 mg , oral solution formulation 10mg/mL ) administer twice Day 1 daily day 2 11 ( 1 hour food ) plus AZD7986 ( 25mg ) single dose Day 6 ( 1 hour food ) ; diltiazem ( 360 mg , extend release formulation ) Days 1 13 ( 1 hour food ) plus AZD7986 ( 25 mg ) 1 hour food Day 8 .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedure . 2 . Healthy male and/or female subject age 18 55 year ( inclusive ) suitable vein cannulation repeat venepuncture . 3 . Females must negative pregnancy test screen admission unit , must lactate must nonchildbearing potential , confirm screen fulfil 1 follow criterion : Postmenopausal define amenorrhea least 12 month follow cessation exogenous hormonal treatment folliclestimulating hormone ( FSH ) level post menopausal range ( &gt; 40 milliInternational unit [ mIU ] /mL ) . Documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy , tubal ligation . 4 . Have body mass index ( BMI ) 18 30 kg/m2 , inclusive , weigh least 50 kg 100 kg , inclusive . 5 . Provision sign , write date informed consent optional genetic/biomarker research . 6 . Hormone replacement therapy allow female exclude drug drug interaction hormone replacement therapy AZD7986 . 1 . History clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study . 2 . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration AZD7986 . 4 . Any clinically significant abnormality clinical chemistry , haematology , urinalysis result , judged investigator . 5 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody . 6 . Any clinically significant abnormal finding vital sign least 10 minute rest , define follow : Systolic blood pressure &lt; 100 mmHg &gt; 140 mmHg ; Diastolic blood pressure &lt; 50 mmHg &gt; 90 mmHg ; Pulse rate &lt; 50 &gt; 85 beat per minute . 7 . Any clinically important abnormality rhythm , conduction morphology rest electrocardiogram ( ECG ) clinically important abnormality 12 Lead ECG consider investigator may interfere interpretation ECG interval measure onset QRS complex ( electrical activity ventricular contraction ECG Q represent downward deflection , R represent upward deflection S represent downward one ) end T wave correct heart rate ( QTc ) interval change , include abnormal STTwave morphology , particularly protocol define primary lead leave ventricular hypertrophy . 8 . Prolonged QT interval correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 m shorten QTcF &lt; 340 m family history long QT syndrome . 9 . PR ( PQ ) interval shorten &lt; 120 m ( PR &gt; 110 m &lt; 120 m acceptable evidence ventricular preexcitation ) . 10 . PR ( PQ ) interval prolongation &gt; 200 m , intermittent second third degree atrioventricular ( AV ) block ( Wenckebach block asleep exclusive ) , AV dissociation . 11 . Persistent intermittent complete bundle branch block ( BBB ) , incomplete bundle branch block ( IBBB ) , intraventricular conduction delay ( IVCD ) QRS &gt; 110 m . Subjects QRS &gt; 110 m &lt; 115 m acceptable evidence e.g. , ventricular hypertrophy preexcitation . 12 . Known suspected history drug abuse , judge investigator . 13 . Current smoker smoke used nicotine product within 3 month screen . 14 . Known suspected history alcohol drug abuse excessive intake alcohol judge investigator . 15 . Positive screen drug abuse cotinine screen admission study centre positive screen alcohol admission study unit . 16 . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD7986 . 17 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea , chocolate , ) judge investigator . 18 . Use drug enzymeinducing property St John 's Wort within 3 week prior first administration AZD7986 . 19 . Use prescribed nonprescribed medication include antacid drug gastric acidrelated disorder , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior first administration AZD7986 long medication long halflife . Note : Hormonal replacement therapy allow female . 20 . Plasma donation within 1 month screen blood donation/loss 500 mL 3 month prior screen . 21 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month first administration AZD7986 study . The period exclusion begin 3 month final dose 1 month last visit whichever long . Note : Subjects consent screen , dose study previous phase I study , exclude . 22 . Subjects previously receive AZD7986 . 23 . Involvement AstraZeneca , PAREXEL study site employee close relative . 24 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction , requirement . 25 . Subjects communicate reliably investigator . 26 . Subjects vegans medical dietary restriction . 27 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order . 28 . Subject increase risk infection : History and/or presence tuberculosis ( TB ) ; positive result interferon gamma release assay ( IGRA ) ( i.e. , QuantiFERON TBGold ) , subject resided region tuberculosis mycosis endemic 90 day screen , intend visit region duration study i.e. , desert area , Eastern Europe , Central South America , Africa except Egypt , Russia , Asia , Indonesia . The test may repeat initial test result indeterminate . Oral body temperature &gt; 37.7Â°C Day 1 , judge investigator . Blood neutrophil count &lt; 1.7 x109/L ( Screening Day 1 morning sample ) . Is high riskgroup HIV infection within last 6 month ( i.e. , men unprotected sex men , woman sex without condom men sex men , people sex without condom person live travelled Africa , people inject drug , people sex without condom somebody injected drug , people catch another sexually transmit infection , people receive blood transfusion Africa , Eastern Europe , country former Soviet Union , Asia Central Southern America ) . Other latent chronic infection ( e.g. , recurrent sinusitis , genital ocular herpes , urinary tract infection ) risk infection ( surgery , trauma , significant infection ) within 90 day screen , history skin abscess within 90 day screen . Clinically significant low respiratory tract infection resolve within 4 week prior screen , determine investigator . Subjects active malignancy neoplastic disease previous 5 year superficial basal cell carcinoma . Disease history suggest abnormal immune function . Subjects receive live liveattenuated vaccine 4 week prior dose . Highsensitivity Creactive protein upper limit laboratory reference range screen Day 1 . 29 . Subjects history sign current gingivitis/periodontitis history current hyperkeratosis palm sol exclude . ( Due fact many subject lack functional DPP1 enzyme describe periodontitis palmoplantar hyperkeratosis . ) 30 . Subjects total urinary protein/urine creatinine ratio outside normal range . 31 . Drugs affect CYP3A4 refrain use 3 week prior study commencement thereafter study completion . In addition , follow consider criterion exclusion optional genetic component study : 32 . History bone marrow transplant 33 . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection . 34 . Hypersensitivity verapamil excipients . 35 . History serious cardiac event myocardial infarction . 36 . History sinoatrial block ; sick sinus syndrome ; chronic uncompensated heart failure ( include leave ventricular heart failure ) . 37 . History atrial flutter , atrial fibrillation WolffParkinsonWhite syndrome . 38 . Known hypersensitivity diltiazem excipients . 39 . Known hypersensitivity itraconazole excipients . 40 . Elevated abnormal liver enzymes active liver disease , experience liver toxicity drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Non-randomized</keyword>
	<keyword>Verapamil</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>Diltiazem</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>